| Dr Jose I Marquez, MD | |
|
3288 Moanalua Rd, Honolulu, HI 96819-1469 | |
| (808) 432-0000 | |
| Not Available |
| Full Name | Dr Jose I Marquez |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 9 Years |
| Location | 3288 Moanalua Rd, Honolulu, Hawaii |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619358785 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 125066216 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital | Honolulu, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hawaii Permanente Medical Group Inc | 7618880667 | 541 |
News Archive
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
News outlets describe the fast-food restaurant's move to provide this menu information both in its restaurants and drive-thrus across the country as part of an effort to get ahead of federal menu-labeling requirements.
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
Doctors and researchers from the John Theurer Cancer Center at Hackensack University Medical Center recently presented research updates and clinical trial results of more than 20 innovative studies at the American Society of Hematology (ASH) annual meeting from December 5-8, 2009.
› Verified 3 days ago
| Entity Name | Hawaii Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710945969 PECOS PAC ID: 7618880667 Enrollment ID: O20031106000625 |
News Archive
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
News outlets describe the fast-food restaurant's move to provide this menu information both in its restaurants and drive-thrus across the country as part of an effort to get ahead of federal menu-labeling requirements.
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
Doctors and researchers from the John Theurer Cancer Center at Hackensack University Medical Center recently presented research updates and clinical trial results of more than 20 innovative studies at the American Society of Hematology (ASH) annual meeting from December 5-8, 2009.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jose I Marquez, MD 3288 Moanalua Rd, Honolulu, HI 96819-1469 Ph: (808) 432-0000 | Dr Jose I Marquez, MD 3288 Moanalua Rd, Honolulu, HI 96819-1469 Ph: (808) 432-0000 |
News Archive
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
News outlets describe the fast-food restaurant's move to provide this menu information both in its restaurants and drive-thrus across the country as part of an effort to get ahead of federal menu-labeling requirements.
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
Doctors and researchers from the John Theurer Cancer Center at Hackensack University Medical Center recently presented research updates and clinical trial results of more than 20 innovative studies at the American Society of Hematology (ASH) annual meeting from December 5-8, 2009.
› Verified 3 days ago
Dr. Heidi M. Solberg-shankle, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3288 Moanalua Rd, Honolulu, HI 96819 Phone: 808-432-0000 | |
Dr. Timothy Christopher Laeger, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 888 S King St, Honolulu, HI 96813 Phone: 808-522-3714 | |
Dr. Ina M Vanhest, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 347 N Kuakini St, Honolulu, HI 96817 Phone: 808-547-9593 Fax: 808-599-2714 | |
Dr. Douglas Clark Ostman, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3196 Diamond Head Rd, Honolulu, HI 96815 Phone: 808-923-9009 | |
Dr. Perri K Quan, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3288 Moanalua Rd, Honolulu, HI 96819 Phone: 808-432-0000 | |
Daniel James Hutchens, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1301 Punchbowl St # 1, Honolulu, HI 96813 Phone: 808-538-9011 | |
Kiera Destiny Glodowski, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1337 Lower Campus Rd Ofc 224, Honolulu, HI 96822 Phone: 808-956-7606 |